Advanced Oncotherapy (AVO) – Director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company at a price of 27.5 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,023,946 Ordinary Shares, representing 1.40% of the issued share […]

Advanced Oncotherapy (AVO) – Conversion of loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces thatBracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of […]

Advanced Oncotherapy (AVO) – Conversion of loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share […]

Advanced Oncotherapy (AVO) – Total Voting Rights

Further to the announcement of 7 November 2016, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that due to a clerical error, 24,505 new ordinary shares of 25 pence each in the Company were not issued and allotted of the 266,668 new Ordinary Shares to be issued as […]

Advanced Oncotherapy (AVO) – Additional director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the notification earlier today Dr Enrico Vanni, Non-Executive Director, has today purchased a further 25,000 ordinary shares of 25 pence in the Company at a price of 29.25 pence per Ordinary Share.  Following this transaction, Dr Vanni […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday the Directors below purchased ordinary shares of 25 pence in the Company. Director No of Ordinary Shares purchased   Price paid Resultant shareholding   %  of the issued share capital Dr Michael Sinclair, Executive Chairman 100,000 28.35p 4,728,229 6.51% Dr […]

Advanced Oncotherapy (AVO) – Result of General Meeting

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today all resolutions were passed.download full film iBoy As a result the Board now has authority to utilise the Equity Financing Facility provided by Bracknor, details of which were provided in […]

Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Friday 24 March it signed an additional 12-month convertible and redeemable loan, at a conversion price of 100p, which will provide net funding of £3m, with an option to draw-down a further £2m within the next […]